TrovaGene, Inc. To Present At Two Upcoming Investor Conferences

SAN DIEGO, Feb. 6, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the following 2014 healthcare and investor conferences next week in New York: BIO CEO & Investor Conference and Leerink Global Healthcare Conference.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

2014 BIO CEO & Investor Conference

Trovagene is scheduled to present at the 2014 BIO CEO & Investor Conference at The Waldorf Astoria February 10-11, 2014, New York, NY, on Tuesday, February 11, 2014 at 8:30 a.m. Mr. Schuh will be available for one-on-one meetings during the conference. The presentation will be webcast live at http://www.veracast.com/webcasts/bio/ceoinvestor2014/24222261242.cfm and can also be accessed through our investor relations page at www.trovagene.com. A replay of the presentation will be available at www.trovagene.com and will be archived for 90 days.

Leerink Healthcare Conference 2014

Trovagene is scheduled to present at the Leerink Global Healthcare Conference 2014 at The Waldorf Astoria Hotel in New York, NY on Thursday, February 13, 2014 at 3:30 p.m. Mr. Schuh will be available for one-on-one meetings during the conference. The presentation will be webcast live at http://leerink.metameetings.com/confbook/healthcare14/directlink?ticker=TROV and can also be accessed through the investor relations page at www.trovagene.com. A replay of the presentation will be available at www.trovagene.com and will be archived for 90 days.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2012 and other periodic reports filed with the Securities and Exchange Commission.

SOURCE Trovagene, Inc.